| First Author | Griveau A | Year | 2020 |
| Journal | Aging Cell | Volume | 19 |
| Issue | 4 | Pages | e13122 |
| PubMed ID | 32196928 | Mgi Jnum | J:287545 |
| Mgi Id | MGI:6414735 | Doi | 10.1111/acel.13122 |
| Citation | Griveau A, et al. (2020) The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes. Aging Cell 19(4):e13122 |
| abstractText | Hutchinson-Gilford progeria syndrome (HGPS) is caused by an LMNA mutation that results in the production of the abnormal progerin protein. Children with HGPS display phenotypes of premature aging and have an average lifespan of 13 years. We found earlier that the targeting of the transmembrane protein PLA2R1 overcomes senescence and improves phenotypes in a mouse model of progeria. PLA2R1 is regulating the JAK/STAT signaling, but we do not yet know whether targeting this pathway directly would influence cellular and in vivo progeria phenotypes. Here, we show that JAK1/2 inhibition with ruxolitinib rescues progerin-induced cell cycle arrest, cellular senescence, and misshapen nuclei in human normal fibroblasts expressing progerin. Moreover, ruxolitinib administration reduces several premature aging phenotypes: bone fractures, bone mineral content, grip strength, and a trend to increase survival in a mouse model of progeria. Thus, we propose that ruxolitinib, an FDA-approved drug, should be further evaluated as a drug candidate in HGPS therapy. |
